First-in-human study with ARQ 621, a novel inhibitor of Eg5: Final results from the solid tumors cohort.
L. C. Chen
Research Funding - ArQule
L. S. Rosen
Research Funding - ArQule
T. Iyengar
No relevant relationships to disclose
J. W. Goldman
Research Funding - ArQule
R. Savage
Employment or Leadership Position - ArQule
Stock Ownership - ArQule
J. Kazakin
Employment or Leadership Position - ArQule
Stock Ownership - ArQule
T. C. K. Chan
Employment or Leadership Position - ArQule
Stock Ownership - ArQule
B. E. Schwartz
Employment or Leadership Position - ArQule
Stock Ownership - ArQule
G. Abbadessa
Employment or Leadership Position - ArQule
Stock Ownership - ArQule
D. D. Von Hoff
Research Funding - ArQule